Advanced Search

Oncology & Hematology Coding Alert

NCD:

Prepare for Broader Medicare Coverage of Oral 3-Drug Antiemetic Regimen

Published on Fri Apr 12, 2013

Irinotecan, oxaliplatin, and more may soon join the reasonable and necessary list. Consider yourself on alert if your physician prescribes the oral three-drug antiemetic regimen of aprepitant, a 5HT3 antagonist, and dexamethasone. A proposed decision memo posted by CMS states coverage may soon be expanded to beneficiaries receiving moderately emetogenic chemotherapy (MEC). Brush Up on Current Coverage The existing National [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All